Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

NBTY seals Leiner deal

This article was originally published in The Tan Sheet

  • News

Executive Summary

Nutritional supplement manufacturer and marketer NBTY announced July 14 it completed its purchase of substantially all Leiner Health Products' assets for $371 million (1"The Tan Sheet" June 16, 2008, p. 3)...

You may also be interested in...



NBTY Forced To Hike Prices By Leiner Integration Costs, Shrinking Margins

NBTY plans to raise prices for its Nature's Bounty brand dietary supplements in January 2009 following a 63.8 percent decrease in net income in its latest earnings period

NBTY Leiner Buy Intensifies Supplement Ingredient Competition

The dietary supplement ingredient supply market is set to become more competitive with NBTY's planned acquisition of Leiner Health Products

Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.

Table

View full table

Topics

Tags:
OTC Drugs
Latest Headlines

Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus

EU Could Soon Have Three XBB.1.5 COVID-19 Vaccines For Winter Season

EU Orphan Drug Law Reform Will See Innovation Drop By 12%, Industry Warns

See All
UsernamePublicRestriction

Register

PS101893

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By